+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery

  • ID: 5309345
  • Report
  • March 2021
  • Region: Global
  • 296 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • Astrazeneca Plc.
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • MORE
Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global vascular endothelial growth factor (VEGF) inhibitor market.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:

Where is the largest and fastest growing market for the vascular endothelial growth factor (VEGF) inhibitor? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vascular endothelial growth factor (VEGF) inhibitor market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider vascular endothelial growth factor (VEGF) inhibitor market, and compares it with other markets.

The report covers the following chapters
  • Executive Summary - The executive summary section of the report gives a brief overview and summary of the report
  • Report Structure - This section gives the structure of the report and the information covered in the various sections.
  • Introduction - This section gives the segmentation of the vascular endothelial growth factor (VEGF) inhibitor market by geography, by drug type, by application and by route of administration covered in this report.
  • Market Characteristics - The market characteristics section of the report defines and explains the vascular endothelial growth factor (VEGF) inhibitor market. This chapter includes different products and services covered in the report and basic definitions.
  • Trends and Strategies - This chapter includes some of the major trends shaping the global vascular endothelial growth factor (VEGF) inhibitor market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
  • Impact Of COVID-19 - This section describes the impact of COVID-19 on the vascular endothelial growth factor (VEGF) market.
  • Global Market Size and Growth - This section contains the global historic (2015-2020) and forecast (2020-2025) market value, and drivers and restraints that support and control the growth of the market in the historic and forecast period.
  • Regional Analysis - This section contains the historic (2015-2020), forecast (2020-2025) market value and growth and market share comparison by region.
  • Market Segmentation - This section contains the market value (2015-20) and analysis for different segments.
  • Regional Market Size and Growth - This section contains the region’s market size (2020), historic (2015-2020) and forecast (2020-2025) market value, and growth and market share comparison of major countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
  • Competitive Landscape - This section covers details on the competitive landscape of the global vascular endothelial growth factor (VEGF) inhibitor market, estimated market shares and company profiles for the leading players.
  • Key Mergers and Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Future Outlook and Potential Analysis - This section includes conclusions and recommendations based on findings of the research. This section gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
  • Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Drug Type: Eylea; Avastin; Tagrisso; Tecentriq; Others
2) By Route of Administration: Intravenous; Intravitreal; Oral
3) By Application: Oncology; Ophthalmology

Companies Mentioned: F. Hoffmann-La Roche AG; Bayer AG; Regeneron Pharmaceuticals Inc.; Astrazeneca Plc.; Novartis AG

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; United States

Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, vascular endothelial growth factor (VEGF) inhibitor indicators comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astrazeneca Plc.
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • MORE
1. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction
6.1.1. Segmentation by Geography
6.1.2. Segmentation by Drug Type
6.1.3. Segmentation by Route of Administration
6.1.4. Segmentation by Application

7. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Characteristics
7.1. Segmentation by Drug Type
7.1.1. Avastin (Bevacizumab)
7.1.2. Eylea (Afibercept )
7.1.3. Lucentis (Ranibizumab)
7.1.4. Tagrisso (Osimertinib)
7.1.5. Tecentriq (Atezolizumab)
7.1.6. Other Drugs
7.2. Segmentation by Route of Administration
7.2.1. Oral
7.2.2. Intravenous
7.2.3. Intravitreal
7.3. Segmentation by Application
7.3.1. Oncology
7.3.2. Ophthalmology

8. COVID Impact on the Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
8.1. Negative Impact on VEGF Market Due to Deferred Care
8.2. Impact on Major VEGF Companies in the Market

9. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Trends and Strategies
9.1. Use of Combination Therapy
9.2. Furthering Innovation Through Collaboration
9.3. Robust Research & Development
9.4. Increasing Biosimilar Approvals
9.5. Less Frequent Dosing for Wet Age-Related Macular Degeneration (AMD)

10. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Size and Growth
10.1. Market Size
10.2. Historic Market Growth, 2015 - 2020, Value ($ Million)
10.2.1. Drivers of the Market 2015 - 2020
10.2.2. Restraints on the Market 2015 - 2020
10.3. Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
10.3.1. Drivers of the Market 2020 - 2025
10.3.2. Restraints on the Market 2020 - 2025

11. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Segmentation
11.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
11.1.1. Eylea
11.1.2. Avastin
11.1.3. Lucentis
11.1.4. Tagrisso
11.1.5. Tecentriq
11.1.6. Others
11.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Route of Administration, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
11.2.1. Intravenous
11.2.2. Intravitreal
11.2.3. Oral
11.3. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
11.3.1. Oncology
11.3.2. Ophthalmology

12. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Regional and Country Analysis
12.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, by Region, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
12.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, by Country, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

13. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
13.1. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
13.1.1. Region Information
13.1.2. COVID 19 impact
13.1.3. Market Information
13.1.4. Background Information
13.1.5. Government Initiatives
13.1.6. Regulations
13.1.7. Regulatory Bodies
13.1.8. Major Associations
13.1.9. Taxes levied
13.1.10. Corporate Tax Structure
13.1.11. Investments
13.1.12. Major Companies
13.2. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
13.3. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
13.4. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.5. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.6. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market: Country Analysis
13.7. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
13.8. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
13.8.1. Country Information
13.8.2. COVID 19 impact
13.8.3. Market Information
13.8.4. Background Information
13.8.5. Government Initiatives
13.8.6. Regulations
13.8.7. Regulatory Bodies
13.8.8. Major Associations
13.8.9. Taxes levied
13.8.10. Corporate Tax Structure
13.8.11. Investments
13.8.12. Major Companies
13.9. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
13.10. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
13.11. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.12. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.13. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
13.14. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
13.14.1. Country Information
13.14.2. COVID 19 impact
13.14.3. Market Information
13.14.4. Background Information
13.14.5. Government Initiatives
13.14.6. Regulations
13.14.7. Regulatory Bodies
13.14.8. Major Associations
13.14.9. Taxes levied
13.14.10. Corporate Tax Structure
13.14.11. Investments
13.14.12. Major Companies
13.15. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
13.16. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
13.17. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.18. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.19. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
13.20. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
13.20.1. Country Information
13.20.2. COVID 19 impact
13.20.3. Market Information
13.20.4. Background Information
13.20.5. Government Initiatives
13.20.6. Regulations
13.20.7. Regulatory Bodies
13.20.8. Major Associations
13.20.9. Corporate Tax Structure
13.20.10. Investments
13.20.11. Major Companies
13.21. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
13.22. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
13.23. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.24. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.25. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
13.26. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
13.27. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
13.28. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.29. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.30. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
13.31. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
13.32. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
13.33. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.34. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.35. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
13.36. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
13.37. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
13.38. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
13.39. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

14. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
14.1. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
14.1.1. Region Information
14.1.2. COVID 19 impact
14.1.3. Market Information
14.1.4. Background Information
14.1.5. Government Initiatives
14.1.6. Regulations
14.1.7. Regulatory Bodies
14.1.8. Major Associations
14.1.9. Taxes levied
14.1.10. Corporate Tax Structure
14.1.11. Investments
14.1.12. Major Companies
14.2. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.3. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
14.4. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.5. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.6. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market: Country Analysis
14.7. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
14.8. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
14.8.1. Country Information
14.8.2. COVID 19 impact
14.8.3. Market Information
14.8.4. Background Information
14.8.5. Government Initiatives
14.8.6. Regulations
14.8.7. Regulatory Bodies
14.8.8. Major Associations
14.8.9. Taxes levied
14.8.10. Corporate Tax Structure
14.8.11. Investments
14.8.12. Major Companies
14.9. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.10. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
14.11. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.12. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.13. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
14.14. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.15. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
14.16. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.17. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.18. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
14.19. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
14.20. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
14.21. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
14.22. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

15. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
15.1. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
15.1.1. Region Information
15.1.2. COVID-19 Impact
15.1.3. Market Information
15.1.4. Background Information
15.1.5. Government Initiatives
15.1.6. Regulations
15.1.7. Regulatory Bodies
15.1.8. Major Associations
15.1.9. Taxes Levied
15.1.10. Corporate Tax Structure
15.1.11. Investments
15.1.12. Major Companies
15.2. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
15.3. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
15.4. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
15.5. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
15.6. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market: Country Analysis
15.7. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
15.8. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
15.9. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
15.10. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
15.11. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

16. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
16.1. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
16.1.1. Region Information
16.1.2. COVID 19 impact
16.1.3. Market Information
16.1.4. Background Information
16.1.5. Government Initiatives
16.1.6. Regulations
16.1.7. Regulatory Bodies
16.1.8. Major Associations
16.1.9. Taxes Levied
16.1.10. Corporate Tax Structure
16.1.11. Investments
16.1.12. Major Companies
16.2. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
16.3. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
16.4. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
16.5. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
16.6. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market: Country Analysis
16.7. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
16.8. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
16.8.1. Country Information
16.8.2. COVID-19 Impact
16.8.3. Market Information
16.8.4. Background Information
16.8.5. Government Initiatives
16.8.6. Regulations
16.8.7. Regulatory Bodies
16.8.8. Major Associations
16.8.9. Taxes Levied
16.8.10. Corporate Tax Structure
16.8.11. Investments
16.8.12. Major Companies
16.9. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
16.10. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
16.11. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
16.12. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

17. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
17.1. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
17.1.1. Region Information
17.1.2. COVID 19 Impact
17.1.3. Market Information
17.1.4. Background Information
17.1.5. Government Initiatives
17.1.6. Regulations
17.1.7. Regulatory Bodies
17.1.8. Major Associations
17.1.9. Taxes Levied
17.1.10. Corporate Tax Structure
17.1.11. Major Companies
17.2. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
17.3. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
17.4. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
17.5. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
17.6. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market: Country Analysis
17.7. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
17.8. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
17.9. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
17.10. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
17.11. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

18. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
18.1. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
18.1.1. Region Information
18.1.2. COVID 19 impact
18.1.3. Market Information
18.1.4. Background Information
18.1.5. Government initiatives
18.1.6. Regulations
18.1.7. Regulatory bodies
18.1.8. Major Associations
18.1.9. Taxes Levied
18.1.10. Corporate Tax Structure
18.1.11. Investments
18.1.12. Major Companies
18.2. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
18.3. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
18.4. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
18.5. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

19. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
19.1. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview
19.1.1. Region Information
19.1.2. COVID 19 impact
19.1.3. Market Information
19.1.4. Background Information
19.1.5. Government initiatives
19.1.6. Regulations
19.1.7. Regulatory Bodies
19.1.8. Major Associations
19.1.9. Taxes Levied
19.1.10. Corporate Tax Structure
19.1.11. Investments
19.1.12. Major Companies
19.2. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Historic Market Growth, 2015 - 2020, Value ($ Million)
19.3. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)
19.4. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)
19.5. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application, Historic and Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)

20. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive Landscape
20.1. Company Profiles
20.2. F. Hoffmann-La Roche AG
20.2.1. Company Overview
20.2.2. Products and Services
20.2.3. Business Strategy
20.2.4. Financial Overview
20.3. Bayer AG
20.3.1. Company Overview
20.3.2. Products and Services
20.3.3. Business Strategy
20.3.4. Financial overview
20.4. Regeneron Pharmaceuticals Inc.
20.4.1. Company Overview
20.4.2. Products and Services
20.4.3. Business Strategy
20.4.4. Financial Overview
20.5. Astrazeneca Plc.
20.5.1. Company Overview
20.5.2. Products and Services
20.5.3. Financial Overview
20.6. Novartis AG
20.6.1. Company Overview
20.6.2. Products and Services
20.6.3. Business Strategy
20.6.4. Financial Overview

21. Key Mergers and Acquisitions in the Vascular Endothelial Growth Factor (VEGF) Inhibitor Market
21.1. Abbvie Inc Acquired Allergan plc
21.2. Takeda Pharmaceutical Company Acquired Shire
21.3. Pfizer Inc Acquired Array Biopharma

22. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Opportunities and Strategies
22.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market in 2025 - Countries Offering most New Opportunities
22.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market in 2025 - Segments Offering most New Opportunities
22.3. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market in 2025 - Growth Strategies
22.3.1. Market Trend Based Strategies
22.3.2. Competitor Strategies

23. Vascular Endothelial Growth Factor (VEGF) Inhibitor, Conclusions and Recommendations
23.1. Conclusions
23.2. Recommendations
23.2.1. Product
23.2.2. Price
23.2.3. Place
23.2.4. Promotion
23.2.5. People

24. Appendix
24.1. Market Data Sources
24.2. NAICS Definitions of Industry Covered in This Report
24.3. Research Methodology
24.4. Currencies
24.5. Research Inquiries
24.6. About the Publisher
24.7. Copyright and Disclaimer
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Astrazeneca Plc.
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • MORE
This report describes and explains the global vascular endothelial growth factor (VEGF) inhibitor market and covers 2015 to 2020, termed the historic period, and 2020 to 2025 termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.

The global vascular endothelial growth factor (VEGF) inhibitor market reached a value of nearly $30,312.6 million in 2020, having increased at a compound annual growth rate (CAGR) of 7.8% since 2015. The market is expected to grow from $30,312.6 million in 2020 to $46,635.5 million in 2025 at a rate of 9.0%. The market is then expected to grow at a CAGR of 6.3% from 2025 and reach $63,375.9 million in 2030.

Growth in the historic period resulted from increase in cancer prevalence, strong economic growth in emerging markets, increase in pharmaceutical R&D expenditure, increased healthcare expenditure, government initiatives and rapid growth in elderly population.

Going forward, increasing prevalence of cancer, rising prevalence of age-related macular degeneration (AMD), rise in healthcare expenditure, high potential of emerging economies, high penetration of the biosimilar drugs and increasing geriatric population will drive the growth. Factors that could hinder the growth of the vascular endothelial growth factor (VEGF) inhibitor market in the future include high costs of drugs, rise in interest rates, coronavirus pandemic and side effects.

The vascular endothelial growth factor (VEGF) inhibitor market is segmented by drugs type into Eylea, Avastin, Tagrisso, Tecentriq and others. The Eylea market was the largest segment of the vascular endothelial growth factor (VEGF) inhibitor market segmented by drugs type, accounting for 23.0% of the total in 2020. Going forward, the tecentriq segment is expected to be the fastest growing segment in the vascular endothelial growth factor (VEGF) inhibitor market segmented by drugs type, at a CAGR of 23.0% during 2020-2025.

The vascular endothelial growth factor (VEGF) inhibitor market is segmented by route of administration into intravenous, intravitreal and oral. The intravenous market was the largest segment of the vascular endothelial growth factor (VEGF) inhibitor market segmented by route of administration, accounting for 34.4% of the total in 2020. Going forward, the oral segment is expected to be the fastest growing segment in the vascular endothelial growth factor (VEGF) inhibitor market segmented by route of administration type, at a CAGR of 13.7% during 2020-2025.

The vascular endothelial growth factor (VEGF) inhibitor market is segmented by application into oncology and ophthalmology. The oncology market was the largest segment of the vascular endothelial growth factor (VEGF) inhibitor market segmented by application, accounting for 60.1% of the total in 2020. Going forward, the oncology segment is expected to be the fastest growing segment in the vascular endothelial growth factor (VEGF) inhibitor market segmented by application type, at a CAGR of 10.8% during 2020-2025.

The vascular endothelial growth factor (VEGF) inhibitor market is segmented by geography into Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. North America was the largest region in the global vascular endothelial growth factor (VEGF) inhibitor market, accounting for 49.0% of the total in 2020. It was followed by Asia-Pacific, and then the other regions. Going forward, the fastest-growing regions in the vascular endothelial growth factor (VEGF) inhibitor market will be Eastern Europe, and, South America where growth will be at CAGRs of 14.6% and 13.1% respectively. These will be followed by Africa, and Middle East, where the markets are expected to grow at CAGRs of 12.2% and 12.0% respectively.

The pandemic has negatively impacted the VEGF market as patients opted for deferred care, as they did not want to visit hospitals or clinics to avoid exposure to the virus. According to a study at The China Medical University First Hospital Department of Ophthalmology during the pandemic, the number of patients who received the VEGF inhibitor injections in the hospital from January 2020 to June 2020 declined by 70%, thus negatively impacting the growth of the market.

The vascular endothelial growth factor (VEGF) inhibitor market is highly consolidated, with small number of large players dominating the market. The top 10 companies in the market occupied 99% of market share in the global vascular endothelial growth factor (VEGF) inhibitor market. Major players in the market include F. Hoffmann-La Roche AG, Bayer AG, Regeneron Pharmaceuticals Inc., Astrazeneca Plc. and Novartis AG.

The top opportunities in the vascular endothelial growth factor (VEGF) inhibitor market segmented by drugs type will arise in the tecentriq segment, which will gain $4,596.9 million of global annual sales by 2025. The top opportunities in segment by route of administration will arise in the oral segment, which will gain $8,830.4 million of global annual sales by 2025. The top opportunities in segment by application will arise in the oncology segment, which will gain $12,263.3 million of global annual sales by 2025. The vascular endothelial growth factor (VEGF) inhibitor market size will gain the most in the USA at $7,015.6 million.

Market-trend-based strategies for the vascular endothelial growth factor (VEGF) inhibitor market include offering combination therapies to patients in order to combat advanced cancers and improve patient life, focusing on strategic collaborations to boost innovations and establish category leadership, investing extensively in R&D activities for the development of effective and innovative drugs, focusing on the production of biosimilars in order to cater to a wider market by making treatment more affordable and focusing on reducing dosages for wet age-related macular degeneration (AMD) in order to improve patient welfare.

Player-adopted strategies in the vascular endothelial growth factor (VEGF) inhibitor market include improving business through new product launches and expanding in newer geographies through strategic collaborations.

To take advantage of the opportunities, the publisher recommends the vascular endothelial growth factor (VEGF) inhibitor market companies to focus on new delivery system, research & development, combination therapy, provide competitively priced offerings, premium pricing for innovator drugs, expand in countries with growing geriatric population, expand in emerging markets, promoting drugs through physicians and NGOs, leverage e-commerce tools to maximize reach and targeting people suffering from cancer and eye disorders.
Note: Product cover images may vary from those shown
4 of 5
  • F. Hoffmann-La Roche AG
  • Bayer AG
  • Regeneron Pharmaceuticals Inc.
  • Astrazeneca Plc.
  • Novartis AG
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll